Compared to Estimates, Jazz (JAZZ) Q3 Earnings: A Look at Key MetricsZacks Investment Research • 11/07/24
Jazz Pharmaceuticals (JAZZ) Q3 Earnings and Revenues Top EstimatesZacks Investment Research • 11/07/24
Insights Into Jazz (JAZZ) Q3: Wall Street Projections for Key MetricsZacks Investment Research • 11/04/24
Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic HypersomniaPRNewsWire • 10/31/24
Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024PRNewsWire • 10/23/24
Billionaire Seth Klarman Sold 64% of Baupost's Stake in Alphabet and Is Piling Into This Historically Cheap and Under-the-Radar DrugmakerThe Motley Fool • 10/18/24
Wall Street Analysts Think Jazz (JAZZ) Could Surge 51.8%: Read This Before Placing a BetZacks Investment Research • 10/17/24
Are Investors Undervaluing Jazz Pharmaceuticals (JAZZ) Right Now?Zacks Investment Research • 10/17/24
JAZZ Stock Soars After Combo Therapy Meets Goal in Lung Cancer StudyZacks Investment Research • 10/16/24
Jazz Pharmaceuticals' Zepzelca/Tecentriq Combo Regimen Can Potentially Delay Disease Progression, Extend Survival In Aggressive Form Of Lung CancerBenzinga • 10/15/24
Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung CancerPRNewsWire • 10/15/24
Jazz Pharmaceuticals: Unveiling Growth Potential From Non-Small Cell Lung Cancer MarketGuruFocus • 10/04/24
Here's Why You Should Consider Buying Jazz Pharmaceuticals' StockZacks Investment Research • 10/02/24
Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024PRNewsWire • 09/16/24
Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024PRNewsWire • 09/09/24
Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024PRNewsWire • 09/05/24
Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share RepurchasesPRNewsWire • 09/04/24
Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share RepurchasesPRNewsWire • 09/03/24